Feed / ALGN

Align Technology, Inc.

ALGN

Healthcare · 150.77 -1.4% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

Align Technology, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 17 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Company-1.4% todayVolume comparison unavailable
Market group0 of 17 activeNo Coherent Theme · unavailable
Disclosed network0 of 2 confirmingNo filing-linked name is confirming now
What would change this read
  • R&D spending rose as Align cited higher employee costs, outside services, software-related depreciation, and cloud tools.

Invalidation: The isolated read changes if ALGN's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Instruments & Supplies

No new filing conclusion is available. 0 of 17 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • R&D spending rose as Align cited higher employee costs, outside services, software-related depreciation, and cloud tools.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations601
Usable filing statements134
Verified relationships3
Evidence supporting the case
  • Foreign exchange has repeated favorable evidence across 5 filings.
Evidence challenging the case
  • Operating margin changed -1.7 percentage points in the latest annual period.
  • Input and raw-material costs has repeated adverse evidence across 5 filings.
  • Product pipeline and R&D has repeated adverse evidence across 5 filings.
Questions before a position
  • EV/sales is 40% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

150.77
6m-13.8%12m+10.9%24m-33.4%
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$4.0B+59.9%$9.69+0.6%
2022-12-31$3.7B-5.5%$4.61-1.6%
2023-12-31$3.9B+3.4%$5.81-2.4%
2024-12-31$4.0B+3.5%$5.62-2.1%
2025-12-31$4.0B+0.9%$5.65-3.2%

What management says matters

Persistent and emerging business drivers

Foreign exchangepositive · 5 filings
For the six months ended June 30, 2026, other income (expense), net decreased compared to the same period in 2025, primarily due to an unfavorable impact from foreign exchange rates, partially offset by a gain recorded on our equity investment.
10-Q · Aug 5, 2026
Input and raw-material costsnegative · 5 filings
For the six months ended June 30, 2026, research and development expense increased compared to the same period in 2025 , primarily due to higher employee costs, including salaries, fringe benefits and bonus costs, depreciation on capitalized labor costs relat…
10-Q · Aug 5, 2026
Product pipeline and R&Dnegative · 5 filings
For the six months ended June 30, 2026, research and development expense increased compared to the same period in 2025 , primarily due to higher employee costs, including salaries, fringe benefits and bonus costs, depreciation on capitalized labor costs relat…
10-Q · Aug 5, 2026
Labor availability and costsnegative · 3 filings
For the six months ended June 30, 2026, research and development expense increased compared to the same period in 2025 , primarily due to higher employee costs, including salaries, fringe benefits and bonus costs, depreciation on capitalized labor costs relat…
10-Q · Aug 5, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 2.7× · EV/sales 2.4×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

150.77-1.4% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for ALGN. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for ALGN. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind ALGN

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

JYNTFiling-linked namepartnerFeb 27, 2026

In 2021, we initiated Joint development (“JDA”) and Technology license agreements (“TLA”) to provide us with access to Cubicure’s technology.

Depended on by

SOLVSolventum CorporationcompetitorFeb 27, 2026

Principal multinational competitors within the oral care market include Dentsply Sirona, Envista, and Straumann, all of which compete with both dental and orthodontic solutions, and Ivoclar, which competes with only dental solution offerings, and Align Techno…

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ALGN is currently a Participant in the organic co-movement group No Coherent Theme. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for ALGN; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.